Highest-materiality recent filing
Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall
Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.
Biote Q4 revenue $46.4M; net income $2.6M; anticipates procedure growth H2 2026
Q4 2025 revenue $46.4M, gross margin 68.0%; net income $2.6M ($0.06 diluted EPS), down from $3.5M ($0.10) in Q4 2024.
Biote Q3 2025: Revenue $48.0M, net income $9.2M ($0.22 EPS), down YoY
Revenue $48.0M, gross profit margin 71.8%.
Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%
Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.
On June 5, 2025, the Board of Directors (the “Board”) of biote Corp. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee, appointed Richard R. Barrera to serve as a member of the Board to fill the vacancy created by the prior resignation of Steven J. Heyer
vacancy created by the prior resignation of Steven J. Heyer
On June 2, 2025, Steven J. Heyer notified the Board of Directors (the “Board”) of biote Corp. (the “Company”) of his resignation as a member of the Board, effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event earnings